Loading…

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase

Although humoral responses against CTL epitope peptides from lymphocyte‐specific protein tyrosine kinase (Lck) antigen have been observed in the majority of healthy donors and cancer patients, the biological activity of the antibody has not been determined. We investigated the biological activity of...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2018-03, Vol.109 (3), p.611-617
Main Authors: Matsueda, Satoko, Itoh, Kyogo, Shichijo, Shigeki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although humoral responses against CTL epitope peptides from lymphocyte‐specific protein tyrosine kinase (Lck) antigen have been observed in the majority of healthy donors and cancer patients, the biological activity of the antibody has not been determined. We investigated the biological activity of mAb against CTL epitope peptide of Lck antigen at positions 486‐494 (anti‐Lck‐486 mAb). This mAb induced dendritic cell maturation from murine bone marrow cells by the immune complex form in vitro, and inhibited tumor growth in association with a suppression of tumor‐infiltrating T cells, including T regulatory cells in a murine model using female BALB/cCrlCrlj mice (H‐2Kd). More potent tumor inhibition was observed when this mAb was given prior to peptide vaccination. These results may help to unveil the biological activity of anti‐Lck peptide antibodies against CTL epitope peptides. Anti‐Lck486 monoclonal antibody induced dendritic cell maturation from murine bone marrow cells in vitro, and inhibited tumor growth in association with a suppression of tumor infiltrating T cells in a murine model using the BALB/cCrlCrlj mice. More potent tumor inhibition was observed when this monoclonal antibody was administered prior to the peptide vaccination.
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.13522